Ascendiant Capital Markets Boosts PAVmed (NASDAQ:PAVM) Price Target to $19.50

PAVmed (NASDAQ:PAVM) had its price objective raised by equities research analysts at Ascendiant Capital Markets from $19.00 to $19.50 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock.

PAVmed Price Performance

NASDAQ PAVM opened at $0.71 on Monday. The company has a fifty day moving average of $0.71 and a 200 day moving average of $0.81. The company has a market capitalization of $12.14 million, a PE ratio of -0.16 and a beta of 1.13. PAVmed has a 1 year low of $0.55 and a 1 year high of $2.43.

Institutional Investors Weigh In On PAVmed

A hedge fund recently raised its stake in PAVmed stock. First Manhattan CO. LLC. boosted its position in shares of PAVmed Inc. (NASDAQ:PAVM) by 16.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 700,000 shares of the company’s stock after buying an additional 100,000 shares during the quarter. First Manhattan CO. LLC. owned approximately 6.32% of PAVmed worth $439,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.93% of the company’s stock.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.